3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Rituximab
63
Cyclophosphamide
37
Brentuximab Vedotin
22
Bendamustine Hydrochloride
22
pembrolizumab
20
fludarabine
20
Gemcitabine
20
Doxorubicin
20
Prednisone
19
ibrutinib
17
Vincristine
16
obinutuzumab
14
Lenalidomide
13
Nivolumab
10
Rifampin
8
parsaclisib
7
duvelisib
7
atezolizumab
7
Vorinostat
7
Dexamethasone
7
Azacitidine
7
spartalizumab
6
loncastuximab tesirine
6
MLN 8237
6
venetoclax
5
ixazomib
5
glofitamab
5
fludarabine phosphate
5
durvalumab
5
acalabrutinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled